{"id":"W2054614641","doi":"10.1111/j.1468-1293.2008.00660.x","title":"Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)<sup>*</sup>","year":2009,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hamilton Health Sciences","funders":"GlaxoSmithKline","keywords":"Medicine; Lopinavir/ritonavir; Ritonavir; Lopinavir; Adverse effect; Pharmacokinetics; Population; Lamivudine; Dosing; Zidovudine; CCR5 receptor antagonist; Internal medicine; Gastroenterology; Nausea; Pharmacology; Viral load; Virology; Virus; Viral disease; Antiretroviral therapy; Hepatitis B virus; Receptor; Chemokine receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005145408,0.0002962954,0.0007874947,0.0003161573,0.00005949779,0.000004203047,0.0001129797,0.00009167087,0.00001175902],"category_scores_gemma":[0.0001372385,0.0001726394,0.0000430246,0.0007845705,0.0002469401,0.0001369913,0.00003755444,0.0002980316,0.000001839109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001630375,"about_ca_system_score_gemma":0.0001138597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002452949,"about_ca_topic_score_gemma":0.000164684,"domain_scores_codex":[0.9977968,0.0002391906,0.0006882813,0.000397007,0.0006093524,0.0002693342],"domain_scores_gemma":[0.998933,0.0001748784,0.0003004483,0.0003931911,0.0001282966,0.0000702313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006318154,0.006094818,0.9538757,0.00006114833,0.00009184212,0.00005703441,0.009794345,0.000009339872,0.0005583975,0.00007116659,0.0002182787,0.02284984],"study_design_scores_gemma":[0.05296109,0.003409932,0.939273,0.001008054,0.00008544244,0.000008234846,0.001058086,0.0001828351,0.00151594,0.00004675994,0.0003045459,0.0001460946],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914405,0.0001414342,0.00001571104,0.00494552,0.0000296262,0.001970336,0.00002617402,0.00001928641,0.001411419],"genre_scores_gemma":[0.9987851,0.0002315774,0.00007455652,0.00009561441,0.00002776535,0.0000237668,0.0001137127,0.00001683883,0.0006310576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04664294,"threshold_uncertainty_score":0.704003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01032576043088261,"score_gpt":0.2569921573094452,"score_spread":0.2466663968785626,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}